Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and ...

With over 3,200 cases already reported this season and FDA-approved immunizations now available, medical professionals urge ...

Giving the long-acting monoclonal antibody nirsevimab to most infants sharply reduced hospitalizations and clinic visits ...

Doctors at Intermountain Health are seeing a big difference in infant hospitalizations for RSV after pushing for Utahns to ...

As the number of RSV infections rises, two recent studies found that protecting babies against the disease prevented ...

Infants who receive nirsevimab may have a lower risk for hospitalisation for RSV-related lower respiratory tract infection ...

RSV often looks like a cold – but sometimes it's more serious. Here's when to call the doctor and how to help your child feel ...

Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory infections among infants, particularly ...

The study included 31,900 infants, 49.1% of whom received nirsevimab. HealthDay News — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower ...

A new shot is helping protect more babies from RSV. A Dayton doctor said it is already dramatically reducing hospitalizations ...

From the balance beam to tackling motherhood, meet Olympic Gold-medal gymnast Shawn Johnson East, who is no stranger to ...

Hull is facing a surge in respiratory infections in children, a doctor said. Dr Kavitha Tharian, a consultant in paediatrics ...